NasdaqGM:BLCM

Stock Analysis Report

Executive Summary

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally.

Snowflake

Fundamentals

High growth potential and fair value.

Risks

  • Bellicum Pharmaceuticals has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Bellicum Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.2%

BLCM

1.0%

US Biotechs

-0.6%

US Market


1 Year Return

-81.4%

BLCM

-10.8%

US Biotechs

0.6%

US Market

BLCM underperformed the Biotechs industry which returned -11.4% over the past year.

BLCM underperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

BLCMIndustryMarket
7 Day-4.2%1.0%-0.6%
30 Day18.0%-0.7%2.2%
90 Day-48.6%-1.8%1.1%
1 Year-81.4%-81.4%-10.1%-10.8%2.9%0.6%
3 Year-94.5%-94.5%5.8%2.2%44.6%35.2%
5 Yearn/a3.8%-1.2%61.9%44.2%

Price Volatility Vs. Market

How volatile is Bellicum Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bellicum Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Bellicum Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Bellicum Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Bellicum Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.

Bellicum Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Bellicum Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Bellicum Pharmaceuticals is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Bellicum Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

37.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Bellicum Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Bellicum Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.

Bellicum Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

Bellicum Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.

Bellicum Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Bellicum Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Bellicum Pharmaceuticals performed over the past 5 years?

-13.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Bellicum Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Bellicum Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Bellicum Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Bellicum Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Bellicum Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Bellicum Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Bellicum Pharmaceuticals's financial position?


Financial Position Analysis

Bellicum Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Bellicum Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Bellicum Pharmaceuticals's level of debt (119.7%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (6.3% vs 119.7% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.6x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Bellicum Pharmaceuticals has less than a year of cash runway based on current free cash flow.

Bellicum Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 12% each year.


Next Steps

Dividend

What is Bellicum Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Bellicum Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Bellicum Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Bellicum Pharmaceuticals has not reported any payouts.

Unable to verify if Bellicum Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Bellicum Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Bellicum Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Rick Fair (50yo)

2.7yrs

Tenure

US$3,278,125

Compensation

Mr. Richard A. Fair, also known as Rick, serves as Director of Clovis Oncology, Inc since October 11, 2018.served as Chief Executive Officer and President of Bellicum Pharmaceuticals, Inc. since January 31 ...


CEO Compensation Analysis

Rick's remuneration is higher than average for companies of similar size in United States of America.

Rick's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.3yrs

Average Tenure

52yo

Average Age

The average tenure for the Bellicum Pharmaceuticals management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.0yrs

Average Tenure

57yo

Average Age

The tenure for the Bellicum Pharmaceuticals board of directors is about average.


Insider Trading

More shares have been bought than sold by Bellicum Pharmaceuticals individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$50,00011 Sep 19
Richard Fair
EntityIndividual
Role
Chief Executive Officer
President
Shares40,000
Max PriceUS$1.25
BuyUS$9,82230 Aug 19
Shane Ward
EntityIndividual
Role
Chief Legal Officer
General Counsel & Corporate Secretary
Shares8,000
Max PriceUS$1.23
BuyUS$19,78023 Aug 19
Richard Fair
EntityIndividual
Role
Chief Executive Officer
President
Shares20,000
Max PriceUS$0.99
BuyUS$45,60013 Nov 18
Jon Stonehouse
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,000
Max PriceUS$4.56

Ownership Breakdown


Management Team

  • Atabak Mokari (42yo)

    Chief Financial Officer

    • Tenure: 0.8yrs
  • Alan Smith (61yo)

    Executive Vice President of Technical Operations

    • Tenure: 3.9yrs
    • Compensation: US$1.05m
  • Tom Farrell (56yo)

    Consultant

    • Tenure: 2.7yrs
    • Compensation: US$1.72m
  • Greg Naeve (54yo)

    Chief Business Officer

    • Tenure: 2.1yrs
  • Rick Fair (50yo)

    President

    • Tenure: 2.7yrs
    • Compensation: US$3.28m
  • Shane Ward (44yo)

    General Counsel & Corporate Secretary

    • Tenure: 1.3yrs
    • Compensation: US$1.15m
  • Aaron Foster

    Head of Research & Senior VP

    • Tenure: 0.5yrs
  • Rosie Williams

    Interim Principal Accounting Officer

    • Tenure: 1.1yrs
  • Joseph Woodard

    Senior Vice President of Clinical & Medical Affairs

    • Tenure: 0.4yrs

Board Members

  • Steve Davis (58yo)

    Director

    • Tenure: 4.2yrs
    • Compensation: US$124.47k
  • James Brown (54yo)

    Chairman of the Board

    • Tenure: 4.8yrs
    • Compensation: US$145.51k
  • Ed Harrigan (66yo)

    Director

    • Tenure: 1.6yrs
    • Compensation: US$208.30k
  • Jim Daly (57yo)

    Director

    • Tenure: 3.3yrs
    • Compensation: US$103.73k
  • Jon Stonehouse (58yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$128.79k
  • David Spencer (57yo)

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0.5yrs
  • Rick Fair (50yo)

    President

    • Tenure: 2.7yrs
    • Compensation: US$3.28m
  • Reid Huber (47yo)

    Director

    • Tenure: 4.9yrs
    • Compensation: US$125.66k
  • Judith Klimovsky (61yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: US$136.99k
  • Malcom Brenner

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0.5yrs

Company Information

Bellicum Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bellicum Pharmaceuticals, Inc.
  • Ticker: BLCM
  • Exchange: NasdaqGM
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$52.730m
  • Shares outstanding: 46.25m
  • Website: https://www.bellicum.com

Number of Employees


Location

  • Bellicum Pharmaceuticals, Inc.
  • 2130 West Holcombe Boulevard
  • Suite 800
  • Houston
  • Texas
  • 77030
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BLCMNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDDec 2014
BPXDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2014
0HMSLSE (London Stock Exchange)YesCommon StockGBUSDDec 2014

Biography

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, an ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 00:20
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.